Skip to content
Monday 17 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,720.30
-0.28%
DAX
26,338.61
-0.38%
CAC 40
8,579.60
-0.66%
STOXX 50
6,530.45
-0.14%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Thursday 21 August 2014 11:45 am  |  Updated:  Friday 07 June 2019 5:56 am

“Today is a miraculous day”: US Ebola doctor treated with ZMapp discharged from hospital

By: Emma Haslett

Add as a preferred source on Google

Two Americans who contracted Ebola while they were working in Liberia have been discharged from a hospital in Atlanta.

Dr Kent Brantly and Nancy Writebol were among the first human patients treated with ZMapp, an experimental drug made by US-based Mapp Biopharmaceutical. Before it was rushed to Liberia to be used on patients during the latest outbreak, the drug had only been tested on monkeys. 

Standing on the steps of Emory University Hospital, Brantly said: "Today is a miraculous day. I am thrilled to be alive."

Dr Bruce Ribner, director of the hospital's infectious disease unit, added:

After a rigorous course of treatment and testing, the Emory Healthcare team has determined that both patients have recovered from the Ebola virus and can return to their families and community without concern for spreading this infection to others.

This year, more than 1,300 people have died of the virus in Guinea, Liberia, Sierra Leone and Nigeria, according to the World Health Organisation (WHO). Companies including Fujifilm and GSK are currently testing drugs, but there is no proven cure. 

 

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Ebola

Trending Articles

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • US bond market jitters spark UK economy recession warning

  • Is the Zeekr 9X Super Hybrid the new luxury SUV to beat?

  • Grandparents fund university degrees to avoid inheritance tax net

  • Aldi boss wades into supermarket ‘price-gouging’ row

More from Morning Wire

  • Ignore Palantir’s political opponents and look at the data: this technology helps patients

    Opinion
    NHS logo on a white surface with visible water droplets, blue and white branding
  • New Victoria Hospital Goes Live with MEDITECH Expanse to Deliver New Era of Care

    Business Wire
  • Iksuda receives US FDA IND clearance for IKS04

    Business Wire
  • NHS data counters claims that £330m Palantir deal has led to ‘no improvement’

    Tech
    Brit are seeking financial support from the ‘Bank of Mum and Dad’ to afford private healthcare.
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

    Business Wire
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook